An exploratory analysis of extracellular vesicle-associated and soluble cytokines in cancer-related fatigue in men with prostate cancer.
Cancer-related fatigue
Cytokines
Exosomes
Extracellular vesicles
Journal
Brain, behavior, & immunity - health
ISSN: 2666-3546
Titre abrégé: Brain Behav Immun Health
Pays: United States
ID NLM: 101759062
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
01
09
2020
accepted:
04
09
2020
entrez:
30
9
2021
pubmed:
1
10
2021
medline:
1
10
2021
Statut:
epublish
Résumé
Cancer Related Fatigue (CRF) is one of the most prevalent and distressing symptoms associated with cancer treatments. The exact etiology of CRF and its mechanisms are poorly understood. Cytokine dysregulation was hypothesized to be one of these mechanisms. Here, we explored the associations of soluble and extracellular vesicle (EV)-associated markers that include cytokines, heat shock proteins (hsp27, hsp70, hsp90), and neurotrophic factors (BDNF) with CRF. Plasma was collected from men (n = 40) with non-metastatic prostate cancer receiving external beam radiation therapy (EBRT) at the start of the treatment, and three months after EBRT. CRF was assessed using the Functional Assessment of Cancer Therapy - Fatigue (FACT-F) from all participants. EVs were characterized via Nanoparticle Tracking Analysis, electron microscopy, and Western blot. Concentrations of EV-associated and soluble markers were measured with a multiplexed immunoassay system. Bivariate correlation analyses and independent T tests analyzed the relationships of CRF with the markers. As CRF worsened, concentrations of EV-associated markers were upregulated. EV-associated fold changes of Eotaxin, hsp27, IP-10, MIP-3α, were significantly higher in fatigued participants compared to non-fatigued EBRT participants three months after treatment. This was not observed in soluble markers. Concentrations of EV-associated CRP and MCP-1, soluble survivin, IFNα2, IL-8, IL-12p70, and MCP-1 significantly correlated with lower (worsening) CRF scores at the start of and three months after treatment. Concentrations of EV-associated markers increased in fatigued men with prostate cancer three months after EBRT. Both EV-associated and soluble markers correlated with worsening CRF. EV-associated markers, which have not been previously studied in depth, may provide additional insights and serve as potential biomarkers for CRF.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer Related Fatigue (CRF) is one of the most prevalent and distressing symptoms associated with cancer treatments. The exact etiology of CRF and its mechanisms are poorly understood. Cytokine dysregulation was hypothesized to be one of these mechanisms. Here, we explored the associations of soluble and extracellular vesicle (EV)-associated markers that include cytokines, heat shock proteins (hsp27, hsp70, hsp90), and neurotrophic factors (BDNF) with CRF.
METHODS
METHODS
Plasma was collected from men (n = 40) with non-metastatic prostate cancer receiving external beam radiation therapy (EBRT) at the start of the treatment, and three months after EBRT. CRF was assessed using the Functional Assessment of Cancer Therapy - Fatigue (FACT-F) from all participants. EVs were characterized via Nanoparticle Tracking Analysis, electron microscopy, and Western blot. Concentrations of EV-associated and soluble markers were measured with a multiplexed immunoassay system. Bivariate correlation analyses and independent T tests analyzed the relationships of CRF with the markers.
FINDINGS
RESULTS
As CRF worsened, concentrations of EV-associated markers were upregulated. EV-associated fold changes of Eotaxin, hsp27, IP-10, MIP-3α, were significantly higher in fatigued participants compared to non-fatigued EBRT participants three months after treatment. This was not observed in soluble markers. Concentrations of EV-associated CRP and MCP-1, soluble survivin, IFNα2, IL-8, IL-12p70, and MCP-1 significantly correlated with lower (worsening) CRF scores at the start of and three months after treatment.
INTERPRETATION
CONCLUSIONS
Concentrations of EV-associated markers increased in fatigued men with prostate cancer three months after EBRT. Both EV-associated and soluble markers correlated with worsening CRF. EV-associated markers, which have not been previously studied in depth, may provide additional insights and serve as potential biomarkers for CRF.
Identifiants
pubmed: 34589888
doi: 10.1016/j.bbih.2020.100140
pii: S2666-3546(20)30105-8
pmc: PMC8474622
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100140Informations de copyright
© 2020 Published by Elsevier Inc.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Pain Symptom Manage. 1997 Feb;13(2):63-74
pubmed: 9095563
Gene. 2015 Aug 10;567(2):132-7
pubmed: 25982860
J Cell Physiol. 2020 Feb;235(2):725-744
pubmed: 31250439
Front Immunol. 2013 Sep 18;4:287
pubmed: 24065967
Cancer Nurs. 2017 May/Jun;40(3):184-193
pubmed: 27105468
FASEB J. 2019 Feb;33(2):1617-1630
pubmed: 30188755
J Psychiatr Res. 2017 Aug;91:130-138
pubmed: 28343068
Cost Eff Resour Alloc. 2004 Jun 21;2(1):4
pubmed: 15210053
J Psychosom Res. 2011 Sep;71(3):136-41
pubmed: 21843747
Front Immunol. 2014 Oct 07;5:491
pubmed: 25339958
Exp Gerontol. 2012 Jan;47(1):52-9
pubmed: 22032874
Autoimmun Rev. 2017 Aug;16(8):845-855
pubmed: 28564620
J Acquir Immune Defic Syndr. 2020 May 1;84(1):45-53
pubmed: 32032302
PLoS Biol. 2019 Jul 18;17(7):e3000363
pubmed: 31318874
Nat Rev Clin Oncol. 2014 Oct;11(10):597-609
pubmed: 25113839
Trends Neurosci. 2014 Jan;37(1):39-46
pubmed: 24239063
World J Biol Psychiatry. 2016 Dec;17(8):608-614
pubmed: 25815565
Support Care Cancer. 2015 Aug;23(8):2461-78
pubmed: 25975676
J Cell Biol. 2013 Feb 18;200(4):373-83
pubmed: 23420871
Platelets. 2017 Mar;28(2):165-173
pubmed: 27595614
Pain. 2014 Aug;155(8):1527-1539
pubmed: 24792623
J Clin Invest. 2003 Jun;111(12):1805-12
pubmed: 12813013
Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1095-103
pubmed: 20231071
Sci Rep. 2018 Jun 12;8(1):8973
pubmed: 29895824
Nat Immunol. 2012 Jul 19;13(8):722-8
pubmed: 22814351
J Exp Med. 2004 May 17;199(10):1343-54
pubmed: 15148334
J Extracell Vesicles. 2015 May 14;4:27066
pubmed: 25979354
J Transl Med. 2009 Nov 12;7:96
pubmed: 19909538
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
Clin Cancer Res. 2009 Sep 1;15(17):5534-40
pubmed: 19706826
Curr Immunol Rev. 2005 Jun;1(2):119-137
pubmed: 21037949
Brain Inj. 2018;32(10):1277-1284
pubmed: 29913077
J Pain Symptom Manage. 2002 Dec;24(6):547-61
pubmed: 12551804
Autoimmun Rev. 2018 Jun;17(6):601-609
pubmed: 29635081
J Extracell Vesicles. 2013 May 27;2:
pubmed: 24009894